The production unit will turn out components for diphtheria and tetanus vaccines.
The new unit will produce 130 million units annually, said GSK managing director Christopher Hunley. He also acknowledged the importance of the companyʼs partnerships with the Hungarian government as well as local universities and other educational institutions.
U.K. ambassador to Hungary Iain Lindsay said GSK laid the foundations for stable business growth in Hungary thanks to the stable economy and a favorable environment for doing business.
Minister of Foreign Affairs and Trade Péter Szijjártó noted that GSK was one of four British companies with whom the government signed strategic agreements earlier.



